ETON Stock Forecast & Price Target

Eton Pharmaceuticals is supported by a rapidly improving commercial engine, highlighted by 2Q26 revenue of $37.6M, up 99% year over year and 55% sequentially, with net income of $0.35 per diluted share and adjusted EBITDA margin of 43%. The HEMANGEOL relaunch appears to be the key catalyst, as nearly 95% of the historical patient base was converted into Eton’s channel by the end of June, helping management raise FY26 revenue guidance to at least $145M and implying strong operating leverage as the company expands volume rather than relying on price. Its outlook is further strengthened by a deep pipeline and capital position, including LIBERVANT’s pending April 2027 launch, DESMODA’s ahead-of-target trajectory, ET-700 and INCRELEX expansion potential, and $26.8M of cash supporting foreseeable funding needs.

Eton Pharmaceuticals is viewed negatively because its valuation remains highly exposed to execution risk across clinical development, commercialization, collaboration, dilution, legal and intellectual property, and competition, while its small scale limits its ability to absorb setbacks. Although the company reported positive GAAP net income for the first time in 3Q24, it has a history of operating losses and may need additional capital through PIPEs, public offerings, or expanded credit facilities if it cannot sustain positive cash flow. Weak adoption of its rare disease portfolio or unfavorable data from late-stage candidates such as ET-600, ET-700, ET-800, Amglidia, and ZENEO hydrocortisone autoinjector could materially impair future value.